☰

cached image

Lon S. Schneider, MD, MS - Publications

Affiliations: 
Psychiatry and the Behavioral Sciences and Neurology University of Southern California, Los Angeles, CA, United States 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=125
Website:
http://www.usc.edu/uscnews/experts/945.html
Tree Info Grants Similar researchers PubMed Report error

355 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kim H, Lee S, Levine A, Huber B, Andrews H, Kerner NA, Cohen D, Carlson S, Bell SA, Rivera AM, Gordon ML, Simoes S, Devanand DP, Brickman AM, Schneider LS, et al. Novel measures of cognition and function for the AD spectrum in the Novel Measures for Alzheimer's Disease Prevention Trials (NoMAD) project: Psychometric properties, convergent validation, and contrasts with established measures. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38963127 DOI: 10.1002/alz.13757  0.344
2024 Lee J, Howard RS, Schneider LS. The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 19: 228-247. PMID 38176792 DOI: 10.1007/s13311-022-01236-5  0.315
2024 Lee J, Howard RS, Schneider LS. The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 19: 228-247. PMID 38176792 DOI: 10.1007/s13311-022-01236-5  0.315
2023 Goldberg TE, Lee S, Devanand DP, Schneider LS. Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 37979967 DOI: 10.1136/jnnp-2023-331941  0.392
2023 Schneider LS. What the Gantenerumab Trials Teach Us about Alzheimer's Treatment. The New England Journal of Medicine. 389: 1918-1920. PMID 37966291 DOI: 10.1056/NEJMe2310903  0.31
2023 Schneider LS. Alzheimer's and Dementia Guidelines and Tables. Psychopharmacology Bulletin. 53: 8-65. PMID 37489152  0.322
2023 LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, et al. A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter. Translational Neurodegeneration. 12: 24. PMID 37173791 DOI: 10.1186/s40035-023-00358-w  0.317
2022 Lee J, Howard RS, Schneider LS. The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 19: 228-247. PMID 35587314 DOI: 10.1007/s13311-022-01236-5  0.315
2022 Wang G, Liu L, Li Y, Aschenbrenner AJ, Bateman RJ, Delmar P, Schneider LS, Kennedy RE, Cutter GR, Xiong C. Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 8: e12286. PMID 35415211 DOI: 10.1002/trc2.12286  0.317
2022 Raikes AC, Hernandez GD, Matthews DC, Lukic AS, Law M, Shi Y, Schneider LS, Brinton RD. Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimer's & Dementia (New York, N. Y.). 8: e12258. PMID 35310526 DOI: 10.1002/trc2.12258  0.304
2021 Schneider LS, Qiu Y, Thomas RG, Evans C, Jacobs DM, Jin S, Kaye JA, LaCroix AZ, Messer K, Salmon DP, Sano M, Schafer K, Feldman HH. Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study. Alzheimer's Research & Therapy. 13: 201. PMID 34930444 DOI: 10.1186/s13195-021-00938-w  0.343
2021 Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJ, et al. Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34590417 DOI: 10.1002/alz.12461  0.347
2021 Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM. Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34590409 DOI: 10.1002/alz.12433  0.367
2021 Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 20: 537-547. PMID 34146512 DOI: 10.1016/S1474-4422(21)00043-0  0.301
2021 Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, et al. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 20: 537-547. PMID 34146512 DOI: 10.1016/S1474-4422(21)00043-0  0.301
2021 Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer's disease trials. The Lancet. Psychiatry. PMID 34087114 DOI: 10.1016/S2215-0366(21)00197-8  0.336
2021 Bell SA, Cohen HR, Lee S, Kim H, Ciarleglio A, Andrews H, Rivera AM, Igwe K, Brickman AM, Devanand DP, Harvey PD, Schneider LS, Goldberg TE. Development of novel measures for Alzheimer's disease prevention trials (NoMAD). Contemporary Clinical Trials. 106425. PMID 33933666 DOI: 10.1016/j.cct.2021.106425  0.336
2021 Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, ... ... Schneider LS, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet. Neurology. PMID 33933186 DOI: 10.1016/S1474-4422(21)00066-1  0.363
2021 Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, et al. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology. PMID 33674360 DOI: 10.1212/WNL.0000000000011774  0.31
2020 Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, et al. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's & Dementia (New York, N. Y.). 6: e12107. PMID 33344752 DOI: 10.1002/trc2.12107  0.33
2020 Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE, Kono N, Buennagel DP, Hazra N, Kim G, D'Orazio LM, McCleary C, Sagare A, Zlokovic BV, Hodis HN, ... ... Schneider LS, et al. Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. Ebiomedicine. 102883. PMID 32690472 DOI: 10.1016/J.Ebiom.2020.102883  0.412
2020 Fowler ME, Triebel KL, Cutter GR, Schneider LS, Kennedy RE. Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease : Jad. PMID 32538844 DOI: 10.3233/Jad-200108  0.42
2020 Schneider LS, Goldberg TE. Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12024. PMID 32432156 DOI: 10.1002/Dad2.12024  0.416
2020 Schneider LS, Goldberg TE. Composite cognitive and functional measures for early stage Alzheimer's disease trials. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12017. PMID 32432155 DOI: 10.1002/Dad2.12017  0.441
2020 Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D'Orazio LM, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, ... Schneider LS, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 581: 71-76. PMID 32376954 DOI: 10.1038/S41586-020-2247-3  0.402
2020 Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 21. PMID 32122400 DOI: 10.1186/S13195-020-00588-4  0.367
2020 Wang G, Kennedy RE, Goldberg TE, Fowler ME, Cutter GR, Schneider LS. Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time. Plos One. 15: e0228064. PMID 32084191 DOI: 10.1371/Journal.Pone.0228064  0.46
2020 Schneider L. A resurrection of aducanumab for Alzheimer's disease. The Lancet. Neurology. 19: 111-112. PMID 31978357 DOI: 10.1016/S1474-4422(19)30480-6  0.435
2019 Schneider LS. Pragmatic Trials and Repurposed Drugs for Alzheimer Disease. Jama Neurology. PMID 31738375 DOI: 10.1001/Jamaneurol.2019.3784  0.428
2019 Ehrhardt S, Porsteinsson AP, Munro CA, Rosenberg PB, Pollock BG, Devanand DP, Mintzer J, Rajji TK, Ismail Z, Schneider LS, Baksh SN, Drye LT, Avramopoulos D, Shade DM, Lyketsos CG, et al. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31587995 DOI: 10.1016/J.Jalz.2019.06.4946  0.505
2019 Wang Y, Hernandez G, Mack WJ, Schneider LS, Yin F, Brinton RD. Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy. Menopause (New York, N.Y.). PMID 31567873 DOI: 10.1097/Gme.0000000000001418  0.356
2019 Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, Schmidt R, Ropele S, Weinstock M. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology. PMID 31492718 DOI: 10.1212/Wnl.0000000000008239  0.379
2019 Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial. Jama Neurology. PMID 31282954 DOI: 10.1001/Jamaneurol.2019.1868  0.374
2019 Ringman JM, Schneider L. Treatment Options for Agitation in Dementia. Current Treatment Options in Neurology. 21: 30. PMID 31231784 DOI: 10.1007/S11940-019-0572-3  0.373
2019 McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. The Cochrane Database of Systematic Reviews. 3: CD003154. PMID 30891742 DOI: 10.1002/14651858.Cd003154.Pub5  0.401
2019 Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30872114 DOI: 10.1016/J.Jalz.2019.01.007  0.389
2019 Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 20-26. PMID 30723776 DOI: 10.1016/J.Trci.2018.11.001  0.423
2019 Lee E, Gatz M, Tseng C, Schneider LS, Pawluczyk S, Wu AH, Deapen D. Evaluation of Medicare Claims Data as a Tool to Identify Dementia. Journal of Alzheimer's Disease : Jad. 67: 769-778. PMID 30689589 DOI: 10.3233/Jad-181005  0.339
2019 Nation DA, Sweeney MD, Montagne A, Sagare AP, D'Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. PMID 30643288 DOI: 10.1038/S41591-018-0297-Y  0.385
2019 Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, et al. Vascular dysfunction-The disregarded partner of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 15: 158-167. PMID 30642436 DOI: 10.1016/J.Jalz.2018.07.222  0.414
2019 Schneider LS, Caggiano AO, Grundman M, DeKosky S, Morgan R, Mozzoni K, Izzo NJ, Safferstein H, Catalano S. CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER’S PATIENTS TREATED WITH CT1812 Alzheimer's & Dementia. 15: P1603-P1604. DOI: 10.1016/J.Jalz.2019.09.072  0.309
2019 Kennedy RE, Fowler ME, Cutter GR, Schneider LS. SEX IS NOT AN IMPORTANT PREDICTOR OF CHANGE IN ALZHEIMER’S CLINICAL TRIAL OUTCOMES Alzheimer's & Dementia. 15: P217-P218. DOI: 10.1016/J.Jalz.2019.06.4567  0.327
2019 Yassine HN, Cordova I, Choe N, Xu W, He X, Kavin B, Kono N, Harrington MG, Fonteh AN, Hodis H, Chui HC, Braskie MN, Mack WJ, Schneider LS. P4-055: DHA SUPPLEMENTATION AND BRAIN DELIVERY PILOT STUDY: A RANDOMIZED CLINICAL TRIAL Alzheimer's & Dementia. 15: P1293-P1294. DOI: 10.1016/J.Jalz.2019.06.3715  0.332
2019 Fowler ME, Cutter GR, Schneider LS, Kennedy RE. P3-548: PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE IN CANCER SURVIVORS Alzheimer's & Dementia. 15: P1183-P1183. DOI: 10.1016/J.Jalz.2019.06.3584  0.388
2019 Wang Y, Solinsky CM, Hernandez GD, Schneider LS, Brinton RD. P3-032: COMBINING SEX, APOE GENOTYPE, AND MITOCHONDRIAL GENETIC VARIANCE AS PREDICTIVE RESPONDER IDENTIFIER TO REGENERATIVE THERAPEUTIC ALLOPREGNANOLONE FOR ALZHEIMER'S DISEASE Alzheimer's & Dementia. 15: P938-P938. DOI: 10.1016/J.Jalz.2019.06.3058  0.342
2019 Shang Y, Hernandez GD, Lopez C, Yin F, Schneider LS, Brinton RD. P3-015: ALLOPREGNANOLONE SHOWS SIGNIFICANT EFFECT ON THE LIPID PATHWAYS FROM PLASMA METABOLOMIC ANALYSIS OF ALZHEIMER'S CLINICAL TRIAL Alzheimer's & Dementia. 15: P930-P930. DOI: 10.1016/J.Jalz.2019.06.3041  0.388
2018 Kennedy RE, Cutter GR, Fowler ME, Schneider LS. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. Jama Network Open. 1: e184080. PMID 30646339 DOI: 10.1001/jamanetworkopen.2018.4080  0.339
2018 Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, ... ... Schneider LS, et al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30555031 DOI: 10.1016/J.Jalz.2018.09.009  0.397
2018 Tao Y, Peters ME, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Munro CA. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias. 1533317518783278. PMID 29969907 DOI: 10.1177/1533317518783278  0.302
2018 Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, et al. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimer's & Dementia (New York, N. Y.). 4: 150-160. PMID 29955659 DOI: 10.1016/J.Trci.2018.02.002  0.497
2018 Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, ... Schneider LS, et al. Precision pharmacology for Alzheimer's disease. Pharmacological Research. PMID 29458203 DOI: 10.1016/J.Phrs.2018.02.014  0.36
2018 Schneider LS. Pimavanserin for patients with Alzheimer's disease psychosis. The Lancet. Neurology. 17: 194-195. PMID 29452674 DOI: 10.1016/S1474-4422(18)30052-8  0.436
2018 Geifman N, Kennedy RE, Schneider LS, Buchan I, Brinton RD. Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. Alzheimer's Research & Therapy. 10: 4. PMID 29370871 DOI: 10.1186/S13195-017-0332-0  0.487
2018 Porsteinsson AP, Devanand DP, Ehrhardt S, Minzter J, Munro CA, Pollock BG, Rajji TK, Rosenberg PB, Shade D, Schneider LS, Lyketsos C. F4-02-02: The S-Citad Study: Trial Design And Methods For The S-Citalopram In Agitation Trial Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2869  0.339
2017 Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, ... ... Schneider LS, et al. Dementia prevention, intervention, and care. Lancet (London, England). PMID 28735855 DOI: 10.1016/S0140-6736(17)31363-6  0.31
2017 Yassine HN, Schneider LS. Lessons from the Multidomain Alzheimer Preventive Trial. The Lancet. Neurology. 16: 585-586. PMID 28721922 DOI: 10.1016/S1474-4422(17)30227-2  0.447
2017 Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, ... ... Schneider LS, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics. PMID 28714976 DOI: 10.1038/Ng.3916  0.335
2017 Kennedy RE, Cutter GR, Wang G, Schneider LS. Challenging Assumptions About African American Participation in Alzheimer Disease Trials. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 28554539 DOI: 10.1016/J.Jagp.2017.04.013  0.475
2017 Charu V, Rosenberg PB, Schneider LS, Drye LT, Rein L, Shade D, Lyketsos CG, Frangakis CE. Characterizing Highly Benefited Patients in Randomized Clinical Trials. The International Journal of Biostatistics. PMID 28541924 DOI: 10.1515/Ijb-2016-0045  0.347
2017 DeKosky ST, Schneider LS. Preventing Dementia: Many Issues and Not Enough Time. Jama Neurology. PMID 28319236 DOI: 10.1001/Jamaneurol.2017.0045  0.328
2017 Schneider LS. Dementia research priorities-2 - Author's reply. The Lancet. Neurology. 16: 182. PMID 28229887 DOI: 10.1016/S1474-4422(17)30018-2  0.34
2017 Schneider LS. Dementia research priorities-1 - Author's reply. The Lancet. Neurology. 16: 181. PMID 28229886 DOI: 10.1016/S1474-4422(17)30019-4  0.34
2017 Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. Alzheimer's Research & Therapy. 9: 10. PMID 28212683 DOI: 10.1186/S13195-017-0237-Y  0.453
2017 Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, Harrington MG, Chui HC. Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review. Jama Neurology. PMID 28114437 DOI: 10.1001/Jamaneurol.2016.4899  0.378
2017 Schneider L. Alzheimer's disease and other dementias: update on research. The Lancet. Neurology. 16: 4-5. PMID 27979354 DOI: 10.1016/S1474-4422(16)30356-8  0.439
2017 Schneider LS, Thomas RG, Hendrix S, Brewer JB, Rissman RA, Salmon DP, Kobayashi H, Feldman HH. A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EDONERPIC (T-817) IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE Alzheimer's & Dementia. 13: P1572. DOI: 10.1016/J.Jalz.2017.07.736  0.354
2017 Kennedy RE, Cutter GR, Schneider LS. CONCOMITANT USE OF CHOLINESTERASE INHIBITORS OR MEMANTINE IS ASSOCIATED WITH COGNITIVE DECLINE IN ALZHEIMER’S CLINICAL TRIALS Alzheimer's & Dementia. 13: P1234. DOI: 10.1016/J.Jalz.2017.07.434  0.366
2017 Irwin RW, Hernandez G, Solinsky CM, Lopez CM, Kono N, Mack WJ, Schneider LS, Diaz Brinton R. [P4-020]: CLINICAL TRIAL RECRUITMENT FRAMEWORK FOR EARLY ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P1262-P1262. DOI: 10.1016/J.Jalz.2017.06.1884  0.475
2016 Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (London, England). PMID 27863809 DOI: 10.1016/S0140-6736(16)31275-2  0.449
2016 Schneider LS. WHO's dementia research priorities: a prescription for failure? The Lancet. Neurology. 15: 1202-1203. PMID 27751538 DOI: 10.1016/S1474-4422(16)30258-7  0.319
2016 Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, ... Schneider LS, et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27583651 DOI: 10.1016/J.Jalz.2016.07.005  0.448
2016 Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimer's Research & Therapy. 8: 25. PMID 27358067 DOI: 10.1186/S13195-016-0194-X  0.436
2016 Ho T, Pollock BG, Mulsant BH, Schantz O, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Drye LT, Munro CA, Shade DM, Lyketsos C, Bies R. R-and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology. PMID 27145364 DOI: 10.1111/Bcp.12997  0.375
2016 Yesavage JA, Taylor JL, Friedman L, Rosenberg PB, Lazzeroni LC, Leoutsakos JS, Kinoshita LM, Perlow MJ, Munro CA, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, et al. Principal components analysis of agitation outcomes in Alzheimer's disease. Journal of Psychiatric Research. 79: 4-7. PMID 27115509 DOI: 10.1016/J.Jpsychires.2016.04.004  0.394
2016 Arai H, Nakamura Y, Taguchi M, Kobayashi H, Yamauchi K, Schneider LS. Mortality risk in current and new antipsychotic AD users: Large scale Japanese study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27106669 DOI: 10.1016/J.Jalz.2016.03.006  0.368
2016 Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, et al. Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. The American Journal of Psychiatry. appiajp201615020248. PMID 27032628 DOI: 10.1016/J.Jalz.2015.06.650  0.445
2016 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, ... ... Schneider LS, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002  0.416
2016 Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, ... ... Schneider LS, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet. Neurology. 15: 455-532. PMID 26987701 DOI: 10.1016/S1474-4422(16)00062-4  0.434
2016 Kennedy RE, Cutter GR, Wang G, Schneider LS. Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. Journal of Alzheimer's Disease : Jad. 50: 1205-15. PMID 26836180 DOI: 10.3233/Jad-150847  0.482
2016 Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, et al. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. The American Journal of Psychiatry. appiajp201515050648. PMID 26771737 DOI: 10.1176/Appi.Ajp.2015.15050648  0.491
2016 Gauthier S, Feldman HH, Schneider LS, Wilcock G, Frisoni GB, Hardlund J, Kook K, Wischik DJ, Schelter BO, Storey JM, Harrington CR, Wischik CM. O4-08-02: Phase 3 Trial of the TAU Aggregation Inhibitor Leuco-Methylthioninium-Bis (Hydromethanesulfonate) (Lmtm) in Mild to Moderate Alzheimer's Disease Alzheimer's & Dementia. 12: P351-P352. DOI: 10.1016/J.Jalz.2016.06.650  0.408
2016 Kennedy RE, Cutter GR, Wang G, Schneider LS. O4-05-06: Limitations of the Fda-Approved ‘Ad Clinical Trial Simulation Tool’ Alzheimer's & Dementia. 12: P344-P344. DOI: 10.1016/J.Jalz.2016.06.636  0.304
2016 Wang G, McDade E, Bateman R, Hassenstab J, Farlow MR, Salloway S, Kennedy RE, Schneider LS, Berry S, Xiong C. P4-004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials Alzheimer's & Dementia. 12: P1015-P1015. DOI: 10.1016/J.Jalz.2016.06.2093  0.338
2016 Margolin RA, Schneider LS, Cutter GR, Breitner JC, Doody RS, Landreth G, Chain D. P3-012: Advancing Therapeutics for Neuroinflammation in Alzheimer's Disease: Clinical Development Considerations Alzheimer's & Dementia. 12: P822-P822. DOI: 10.1016/J.Jalz.2016.06.1669  0.447
2015 Schneider LS. Introducing , an open access journal of the Alzheimer's Association. Alzheimer's & Dementia (New York, N. Y.). 1: 91-93. PMID 29854929 DOI: 10.1016/J.Trci.2015.06.002  0.363
2015 Wang G, Kennedy RE, Cutter GR, Schneider LS. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment. Alzheimer's & Dementia (New York, N. Y.). 1: 63-71. PMID 29854926 DOI: 10.1016/J.Trci.2015.03.002  0.463
2015 Kennedy RE, Cutter GR, Wang G, Schneider LS. Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimer's & Dementia (New York, N. Y.). 1: 46-52. PMID 27695707 DOI: 10.1016/J.Trci.2015.03.001  0.447
2015 Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 103-11. PMID 27239497 DOI: 10.1016/J.Dadm.2014.11.003  0.43
2015 Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, et al. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. Journal of Psychiatric Research. 74: 17-21. PMID 26736036 DOI: 10.1016/J.Jpsychires.2015.12.005  0.477
2015 Hunsberger JG, Rao M, Kurtzberg J, Bulte JW, Atala A, LaFerla FM, Greely HT, Sawa A, Gandy S, Schneider LS, Doraiswamy PM. Accelerating stem cell trials for Alzheimer's disease. The Lancet. Neurology. PMID 26704439 DOI: 10.1016/S1474-4422(15)00332-4  0.411
2015 Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Shade DM, Lyketsos CG. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics. PMID 26611790 DOI: 10.1007/S10928-015-9457-6  0.32
2015 Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, et al. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. International Psychogeriatrics / Ipa. 27: 2059-67. PMID 26305876 DOI: 10.1017/S1041610215001106  0.463
2015 Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. Journal of Geriatric Psychiatry and Neurology. PMID 26303700 DOI: 10.1177/0891988715601735  0.381
2015 Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, et al. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 26238225 DOI: 10.1016/J.Jagp.2015.05.006  0.439
2015 Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. Jama Psychiatry. 72: 438-45. PMID 25786075 DOI: 10.1001/Jamapsychiatry.2014.3018  0.301
2015 Kim HM, Chiang C, Weintraub D, Schneider LS, Kales H. Treatment changes among older patients with dementia treated with antipsychotics. International Journal of Geriatric Psychiatry. PMID 25759986 DOI: 10.1002/Gps.4281  0.327
2015 Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 84: 1121-7. PMID 25681452 DOI: 10.1212/Wnl.0000000000001376  0.375
2015 Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics. 15: 83-105. PMID 25537424 DOI: 10.1586/14737175.2015.995637  0.476
2015 Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, ... ... Schneider LS, et al. Rarity of the Alzheimer disease-protective APP A673T variant in the United States. Jama Neurology. 72: 209-16. PMID 25531812 DOI: 10.1001/Jamaneurol.2014.2157  0.383
2015 Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 24-31. PMID 24613705 DOI: 10.1016/J.Jalz.2013.11.008  0.463
2015 Schneider LS. Introducing Alzheimer's & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer's Association Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 91-93. DOI: 10.1016/j.trci.2015.06.002  0.321
2015 Kennedy RE, Cutter GR, Wang G, Schneider LS. Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 46-52. DOI: 10.1016/j.trci.2015.03.001  0.328
2015 Schneider LS. S3-02-03: Rationally iterating novel trials designs Alzheimer's & Dementia. 11: P211-P211. DOI: 10.1016/J.Jalz.2015.07.220  0.33
2015 Kennedy RE, Wang G, Cutter GR, Schneider LS. O1-10-02: How does differential effect of treatment in ApoE-ɛ4+ carriers change clinical trial design in Alzheimer's disease? Alzheimer's & Dementia. 11: P154-P154. DOI: 10.1016/J.Jalz.2015.07.082  0.438
2015 Wang G, Kennedy RE, Cutter GR, Schneider LS. Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 63-71. DOI: 10.1016/J.Jalz.2013.04.363  0.436
2015 Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 1: 103-111. DOI: 10.1016/j.dadm.2014.11.003  0.362
2014 Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, ... ... Schneider LS, et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S430-52. PMID 25341459 DOI: 10.1016/J.Jalz.2014.08.103  0.396
2014 Schneider LS. Idalopirdine for Alzheimer's disease: written in the stars. The Lancet. Neurology. 13: 1063-5. PMID 25297011 DOI: 10.1016/S1474-4422(14)70232-7  0.402
2014 Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, ... ... Schneider LS, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. Jama Neurology. 71: 1394-404. PMID 25199842 DOI: 10.1001/Jamaneurol.2014.1491  0.333
2014 Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, et al. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. Plos One. 9: e98426. PMID 24914549 DOI: 10.1016/J.Jalz.2014.04.511  0.356
2014 Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. The Lancet. Neurology. 13: 676-85. PMID 24873720 DOI: 10.1016/S1474-4422(14)70088-2  0.361
2014 Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, ... ... Schneider L, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet. Neurology. 13: 614-29. PMID 24849862 DOI: 10.1016/S1474-4422(14)70090-0  0.446
2014 Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. Journal of the American Geriatrics Society. 62: 985-8. PMID 24828933 DOI: 10.1111/Jgs.12816  0.377
2014 Schneider LS. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 247-50. PMID 24698029 DOI: 10.1016/J.Jalz.2013.12.002  0.419
2014 Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine. 275: 251-83. PMID 24605808 DOI: 10.1111/Joim.12191  0.472
2014 Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, Skoog I, Kivipelto M. Advances in the prevention of Alzheimer's disease and dementia. Journal of Internal Medicine. 275: 229-50. PMID 24605807 DOI: 10.1111/Joim.12178  0.47
2014 Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 311: 682-91. PMID 24549548 DOI: 10.1001/Jama.2014.93  0.496
2014 Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L. A new roadmap for drug development for Alzheimer's disease. Nature Reviews. Drug Discovery. 13: 156. PMID 24362362 DOI: 10.1038/Nrd3842-C2  0.432
2014 Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 22: 14-24. PMID 24314887 DOI: 10.1016/J.Jagp.2013.02.014  0.391
2014 Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 349-59. PMID 23712001 DOI: 10.1016/J.Jalz.2013.03.003  0.489
2014 Schneider LS. What we expect from future trials Neurobiology of Aging. 35: S19-S20. DOI: 10.1016/J.Neurobiolaging.2014.01.105  0.337
2014 Schneider LS, Kennedy RE, Wang G, Cutter G. P4-177: BASELINE COGNITIVE SEVERITY DOES NOT PREDICT RATE OF CHANGE IN THE ADAS-COG CLINICAL TRIALS Alzheimer's & Dementia. 10: P853-P854. DOI: 10.1016/J.Jalz.2014.05.1694  0.36
2014 Schneider LS, Kennedy RE, Wang G, Cutter G. P4-176: DIFFERENCES IN ALZHEIMER DISEASE CLINICAL TRIALS OUTCOMES BASED ON AGE OF PATIENTS Alzheimer's & Dementia. 10: P853-P853. DOI: 10.1016/J.Jalz.2014.05.1693  0.427
2014 Lee E, Schneider LS, Jang JY, Lee Tilley J, Kim J, Rodriguez C, Juang C, Deapen D, Gatz M, McCleary CA. P3-332: DEVELOPING STRATEGIES FOR LONGITUDINAL ASSESSMENT OF COGNITIVE FUNCTION IN THE CALIFORNIA TEACHERS STUDY Alzheimer's & Dementia. 10: P751-P751. DOI: 10.1016/J.Jalz.2014.05.1425  0.317
2014 Schneider LS, Kennedy R, Wang G, Cutter G. P2-393: THE USE OF META-DATABASE DATA FOR QUALITY CONTROL IN CLINICAL TRIALS: AN EXAMPLE USING THE MMSE Alzheimer's & Dementia. 10: P623-P623. DOI: 10.1016/J.Jalz.2014.05.1073  0.326
2014 Schneider LS. F5-01-04: RESEARCH EVIDENCE ABOUT DIAGNOSIS, PREVENTION, AND PHARMACEUTICAL INTERVENTIONS FOR ALZHEIMER'S DISEASE IS OVERSOLD Alzheimer's & Dementia. 10: P282-P283. DOI: 10.1016/J.Jalz.2014.04.461  0.35
2014 Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider L, Kales HC. Number Needed to Harm for Antipsychotics and Antidepressants in Dementia The American Journal of Geriatric Psychiatry. 22: S119-S120. DOI: 10.1016/J.Jagp.2013.12.137  0.351
2013 Zhao L, Mao Z, Chen S, Schneider LS, Brinton RD. Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 37: 403-19. PMID 23948892 DOI: 10.3233/Jad-122341  0.395
2013 Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 438-44. PMID 23809364 DOI: 10.1016/J.Jalz.2013.03.007  0.453
2013 Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. The American Journal of Psychiatry. 170: 651-9. PMID 23598969 DOI: 10.1176/Appi.Ajp.2012.12070927  0.305
2013 Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 602-8. PMID 23562430 DOI: 10.1016/J.Jalz.2012.12.001  0.398
2013 Schneider LS. Quantifying an amyloid β model for Alzheimer's disease. The Lancet. Neurology. 12: 327-8. PMID 23477990 DOI: 10.1016/S1474-4422(13)70050-4  0.414
2013 Rettberg J, Mack W, Hodis H, Dang H, Zhao L, Schneider L, Stanczyk F, Brinton R. P2-010: A bioenergetic trajectory of female brain aging and Alzheimer's disease 3: Development of metabolic and physiological biomarker profiles for early detection of women at risk for Alzheimer's disease Alzheimer's & Dementia. 9: P348-P349. DOI: 10.1016/J.Jalz.2013.05.652  0.383
2013 Schneider L, Kennedy R, Wang G, Cutter G. P1-360: Effect of APOE genotype on clinical trial outcomes Alzheimer's & Dementia. 9: P290-P290. DOI: 10.1016/J.Jalz.2013.05.587  0.341
2013 Brinton R, Irwin R, Mack W, Rodgers K, Bauer G, Rogawski M, Schneider L. P4-012: Allopregnanolone as a regenerative therapeutic for Alzheimer's disease, 1: From discovery to phase I multiple-ascending-dose clinical trial Alzheimer's & Dementia. 9: P709-P709. DOI: 10.1016/J.Jalz.2013.05.1400  0.438
2013 Lee E, Deapen D, Gatz M, McCleary CA, Pinder R, Schneider L. P3-165: Alzheimer's disease prevention research in the California Teachers Study cohort Alzheimer's & Dementia. 9: P614-P614. DOI: 10.1016/J.Jalz.2013.05.1237  0.375
2013 Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N. O3-06-06: The neuroprotective and neurotrophic agent T-817MA for Alzheimer's disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes Alzheimer's & Dementia. 9: P530-P531. DOI: 10.1016/J.Jalz.2013.04.272  0.394
2013 Welsh-Bohmer K, Romero H, Hayden K, Plassman B, Germain C, Sano M, Espeland M, Craft S, Monsch A, Schneider L, Chiang C, Haneline S, Oneil J, Malholtra M, Brannan S, et al. O1-06-01: Challenges in international clinical trials to delay early symptomatic Alzheimer's disease Alzheimer's & Dementia. 9: P137-P138. DOI: 10.1016/J.Jalz.2013.04.079  0.438
2012 Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 20: 1036-44. PMID 23032478 DOI: 10.1097/Jgp.0B013E31826Ce4C5  0.445
2012 Kennedy RE, Schneider LS, Cutter GR, Alzheimer's Disease Neuroimaging Initiative. Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Current Alzheimer Research. 9: 1135-41. PMID 22963265 DOI: 10.2174/156720512804142976  0.46
2012 Schneider LS. Ginkgo and AD: key negatives and lessons from GuidAge. The Lancet. Neurology. 11: 836-7. PMID 22959218 DOI: 10.1016/S1474-4422(12)70212-0  0.331
2012 Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, ... ... Schneider L, et al. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. The Journal of Nutrition, Health & Aging. 16: 339-45. PMID 22499454 DOI: 10.1007/S12603-012-0044-X  0.462
2012 Schneider LS. Recruitment methods for United States Alzheimer disease prevention trials. The Journal of Nutrition, Health & Aging. 16: 331-5. PMID 22499452 DOI: 10.1007/S12603-012-0011-6  0.424
2012 Schneider LS. Discontinuing donepezil or starting memantine for Alzheimer's disease. The New England Journal of Medicine. 366: 957-9. PMID 22397659 DOI: 10.1056/Nejme1200429  0.459
2012 Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006395. PMID 22393531 DOI: 10.1101/Cshperspect.A006395  0.423
2012 Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, et al. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 121-30. PMID 22301195 DOI: 10.1016/J.Jalz.2011.01.007  0.454
2012 Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease. The Journal of Clinical Psychiatry. 73: 121-8. PMID 21939611 DOI: 10.4088/Jcp.10M06574  0.424
2012 Miller EA, Rosenheck RA, Schneider LS. Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. International Journal of Geriatric Psychiatry. 27: 382-93. PMID 21560160 DOI: 10.1002/Gps.2730  0.376
2012 Schneider LS. Pharmacological treatment of Alzheimer's disease Advances in Biological Psychiatry. 28: 122-167. DOI: 10.1159/000335407  0.317
2012 Schneider LS. 71 Are we ready to perform clinical trials in early AD patients? which patients, which outcomes? Neurobiology of Aging. 33: S31. DOI: 10.1016/J.Neurobiolaging.2012.01.089  0.389
2012 Schafer K, Sano M, Donohue M, Sun C, Aisen P, Schneider L. P2-288: Performance on ADAS-Cog items across ADCS trials Alzheimer's & Dementia. 8: P363-P364. DOI: 10.1016/J.Jalz.2012.05.996  0.311
2011 Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D, et al. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. Journal of Geriatric Psychiatry and Neurology. 24: 222-8. PMID 22228829 DOI: 10.1177/0891988711422527  0.398
2011 Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Progress in Neurobiology. 95: 594-600. PMID 21925234 DOI: 10.1016/J.Pneurobio.2011.08.014  0.469
2011 Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 77: 1263-71. PMID 21917762 DOI: 10.1212/Wnl.0B013E318230A16C  0.403
2011 Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry. 68: 853-61. PMID 21810649 DOI: 10.1001/Archgenpsychiatry.2011.72  0.431
2011 Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, ... ... Schneider LS, et al. IAGG workshop: health promotion program on prevention of late onset dementia. The Journal of Nutrition, Health & Aging. 15: 562-75. PMID 21808935 DOI: 10.1007/S12603-011-0142-1  0.369
2011 Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The American Journal of Psychiatry. 168: 831-9. PMID 21572163 DOI: 10.1176/Appi.Ajp.2011.08121844  0.503
2011 Schafer K, De Santi S, Schneider LS. Errors in ADAS-cog administration and scoring may undermine clinical trials results. Current Alzheimer Research. 8: 373-6. PMID 21557720 DOI: 10.1016/J.Jalz.2010.05.1658  0.417
2011 Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Archives of Neurology. 68: 991-8. PMID 21482915 DOI: 10.1001/Archneurol.2011.69  0.475
2011 O'Halloran JP, Kemp AS, Salmon DP, Tariot PN, Schneider LS. Psychometric comparison of standard and computerized administration of the Alzheimer’s Disease Assessment Scale: Cognitive Subscale (ADASCog). Current Alzheimer Research. 8: 323-8. PMID 21314622 DOI: 10.2174/156720511795563692  0.37
2011 Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ignacio R, Ganoczy D, Cunningham F, Schneider LS, Blow FC. Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry. 68: 190-7. PMID 21300946 DOI: 10.1001/Archgenpsychiatry.2010.200  0.321
2011 Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 12: 2-32. PMID 21288069 DOI: 10.3109/15622975.2010.538083  0.392
2011 Golde TE, Schneider LS, Koo EH. Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 69: 203-13. PMID 21262461 DOI: 10.1016/J.Neuron.2011.01.002  0.43
2011 Schneider LS, Insel PS, Weiner MW. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Archives of Neurology. 68: 58-66. PMID 21220675 DOI: 10.1001/Archneurol.2010.343  0.478
2011 Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 76: 280-6. PMID 21178097 DOI: 10.1212/Wnl.0B013E318207B1B9  0.463
2011 Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Disease and Associated Disorders. 25: 122-7. PMID 20921876 DOI: 10.1097/Wad.0B013E3181F883B7  0.461
2011 Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? International Journal of Geriatric Psychiatry. 26: 573-83. PMID 20672243 DOI: 10.1002/Gps.2565  0.384
2011 Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. International Psychogeriatrics / Ipa. 23: 44-53. PMID 20214847 DOI: 10.1017/S1041610210000244  0.418
2011 Schafer K, Sano M, Aisen P, Donohue M, Sun C, Schneider L. P1-472: Extent and impact of missing ADAS-cog items in ADCS clinical trials Alzheimer's & Dementia. 7: S264-S264. DOI: 10.1016/J.Jalz.2011.05.754  0.35
2011 Schneider L. F1-02-04: Agitation and Alzheimer's disease Alzheimer's & Dementia. 7: S92-S92. DOI: 10.1016/J.Jalz.2011.05.223  0.361
2011 Schneider L, Kennedy R, Cutter G. O4-01-03: Amnestic MCI/ prodromal Alzheimer's disease with more severe memory deficit is indistinguishable from diagnosed Alzheimer disease: Implications for the validity of clinical trials and biomarkers Alzheimer's & Dementia. 7: S681-S682. DOI: 10.1016/J.Jalz.2011.05.1966  0.461
2011 Zhao L, Mao Z, Schneider L, Brinton R. P3-480: Phyto-beta-SERM formulation for menopause and Alzheimer's disease: From bench to bedside Alzheimer's & Dementia. 7: S669-S669. DOI: 10.1016/J.Jalz.2011.05.1925  0.346
2010 Schneider LS. Fixing Alzheimer disease trials by improving process and methods. Current Alzheimer Research. 7: 564-5. PMID 21214512 DOI: 10.2174/156720510793498995  0.423
2010 Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. Journal of Clinical Psychopharmacology. 30: 683-7. PMID 21105282 DOI: 10.1097/Jcp.0B013E3181Fa05Bb  0.415
2010 Schneider LS. Organising the language of Alzheimer's disease in light of biomarkers. The Lancet. Neurology. 9: 1044-5. PMID 20934913 DOI: 10.1016/S1474-4422(10)70246-5  0.35
2010 Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 367-77. PMID 20813339 DOI: 10.1016/J.Jalz.2010.07.004  0.429
2010 Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 917-27. PMID 20808108 DOI: 10.1097/Jgp.0B013E3181D5745D  0.413
2010 Miller EA, Rosenheck RA, Schneider LS. Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease. Alzheimer Disease and Associated Disorders. 24: 380-9. PMID 20625266 DOI: 10.1097/Wad.0B013E3181Eb2F2E  0.342
2010 Schneider LS. The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. The Journal of Nutrition, Health & Aging. 14: 295-8. PMID 20305999 DOI: 10.1007/S12603-010-0066-1  0.496
2010 Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, ... ... Schneider LS, et al. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 89-97. PMID 20298968 DOI: 10.1016/J.Jalz.2010.01.008  0.413
2010 Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 332-40. PMID 20220589 DOI: 10.1097/Jgp.0B013E3181Cc0333  0.394
2010 Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 18: 136-45. PMID 20087081 DOI: 10.1097/Jgp.0B013E3181C796Eb  0.448
2010 Miller EA, Rosenheck RA, Schneider LS. Assessing the relationship between health utilities, quality of life, and health care costs in Alzheimer's disease: the CATIE-AD study. Current Alzheimer Research. 7: 348-57. PMID 19715552 DOI: 10.2174/156720510791162386  0.338
2010 Fleisher AS, Jack CR, Weiner MW, Truran D, Mai J, Aisen PS, Cummings JL, Thomas RG, Schneider LS, Tariot PN. Brain volume changes with divalproex sodium in Alzheimer's disease Alzheimer's & Dementia. 6: S302-S303. DOI: 10.1016/J.Jalz.2010.05.988  0.363
2010 Schneider LS, Kennedy RE, Cutter GR. O2-02-08: Requiring a CSF amyloid-β42 biomarker for a prodromal AD research diagnosis does not result in better clinical trials: Simulations from the ADNI database Alzheimer's & Dementia. 6: S100-S100. DOI: 10.1016/J.Jalz.2010.05.313  0.369
2010 Schneider LS, Insel PS, Weiner MW. P3-457: Cholinesterase inhibitors and memantine use by patients in the Alzheimer's disease neuroimaging initiative Alzheimer's & Dementia. 6: S587-S588. DOI: 10.1016/J.Jalz.2010.05.2000  0.41
2010 Kemp AS, Mohs R, Salmon D, Tariot P, Ismail MS, Schneider LS, O'Halloran JP. Psychometric comparison of standard and computerized administration of the Alzheimer's Disease Assessment Scale (ADAS) among patients with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1636  0.447
2009 Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama. 302: 2557-64. PMID 20009055 DOI: 10.1001/Jama.2009.1866  0.442
2009 Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. Alzheimer Disease and Associated Disorders. 23: 260-7. PMID 19812469 DOI: 10.1097/Wad.0B013E31819Cb760  0.435
2009 Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 388-97. PMID 19751918 DOI: 10.1016/J.Jalz.2009.07.038  0.454
2009 Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. The American Journal of Psychiatry. 166: 583-90. PMID 19369318 DOI: 10.1176/Appi.Ajp.2008.08081218  0.378
2009 Nelson JC, Delucchi K, Schneider LS. Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis. International Journal of Geriatric Psychiatry. 24: 539-44. PMID 19334041 DOI: 10.1002/Gps.2233  0.302
2009 Schneider LS. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 172-9. PMID 19328454 DOI: 10.1016/J.Jalz.2009.01.023  0.322
2009 Schneider LS, Lahiri DK. The perils of Alzheimer's drug development. Current Alzheimer Research. 6: 77-8. PMID 19199878 DOI: 10.2174/156720509787313871  0.326
2009 Miller EA, Schneider LS, Rosenheck RA. Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease. International Journal of Geriatric Psychiatry. 24: 96-105. PMID 19016254 DOI: 10.1002/Gps.2160  0.324
2009 Schneider LS, Vigen CL, Mack WJ, Sultzer DL, Davis SM, Weintraub D, Lyketsos CG, Zheng L, Dagerman KS, Stroup TS, Hsiao JK, Lebowitz BD, Tariot PN. O4-04-01: Citalopram compared to atypical antipsychotics for Alzheimer patients who did not previously benefit from treatment: The catie-AD study Alzheimer's & Dementia. 5: P156-P156. DOI: 10.1016/J.Jalz.2009.05.540  0.375
2009 Wilcock GK, Black SE, Balch AH, Amato DA, Beelen AP, Schneider LS, Green RC, Swabb EA, Zavitz KH. O1-04-07: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial Alzheimer's & Dementia. 5: P86-P86. DOI: 10.1016/J.Jalz.2009.05.220  0.394
2009 Mohamed S, Rosenheck R, Schneider L. P1-176: Clinical correlates of caregiver burden in Alzheimer's disease Alzheimer's & Dementia. 5: P228-P228. DOI: 10.1016/J.Jalz.2009.04.182  0.441
2009 Aisen PS, Schneider LS, Sano M. High-dose B vitamin supplements and alzheimer disease reply Jama - Journal of the American Medical Association. 301: 1021-1022. DOI: 10.1001/Jama.2009.213  0.31
2008 Schneider LS. Ginkgo biloba extract and preventing Alzheimer disease. Jama. 300: 2306-8. PMID 19017919 DOI: 10.1001/Jama.2008.675  0.444
2008 Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama. 300: 1774-83. PMID 18854539 DOI: 10.1001/Jama.300.15.1774  0.376
2008 Schneider LS. Prevention therapeutics of dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: S122-30. PMID 18631988 DOI: 10.1016/J.Jalz.2007.11.005  0.38
2008 Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 156-63. PMID 18631960 DOI: 10.1016/J.Jalz.2008.03.005  0.454
2008 Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. The American Journal of Psychiatry. 165: 844-54. PMID 18519523 DOI: 10.1176/Appi.Ajp.2008.07111779  0.454
2008 Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 469-77. PMID 18515691 DOI: 10.1097/Jgp.0B013E318165Dbae  0.363
2008 Miller EA, Schneider LS, Zbrozek A, Rosenheck RA. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 1120-30. PMID 18489496 DOI: 10.1111/J.1524-4733.2008.00351.X  0.434
2008 O'Halloran JP, Kemp AS, Gooch KN, Harvey PD, Palmer BW, Reist C, Schneider LS. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophrenia Research. 106: 33-41. PMID 18160262 DOI: 10.1016/J.Schres.2007.11.015  0.308
2008 Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 957-70. PMID 17637610 DOI: 10.1038/Sj.Npp.1301492  0.394
2008 Schneider LS, Dagerman K, Shaikh Z, Insel P. O3-04-08: No secular trend and high variability for ADAS-cog change among placebo groups from clinical trials Alzheimer's & Dementia. 4: T167-T167. DOI: 10.1016/J.Jalz.2008.05.439  0.311
2008 Green RC, Schneider LS, Hendrix SB, Zavitz KH, Swabb E. O3-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month multi-center phase 3 trial Alzheimer's & Dementia. 4: T165-T165. DOI: 10.1016/J.Jalz.2008.05.432  0.393
2008 Schneider LS, Dagerman K, Shaikh Z. P4-394: Lack of evidence for the efficacy of memantine in mild Alzheimer's disease and modest effects in moderate Alzheimer's disease Alzheimer's & Dementia. 4: T790-T790. DOI: 10.1016/J.Jalz.2008.05.2464  0.357
2008 Raman R, Emond J, Thomas RG, Petersen RC, Schneider LS, Aisen PS, Sano M. P4-387: Adding delayed recall to the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog): Sensitivity in a clinical trial for Alzheimer's disease and mild cognitive impairment Alzheimer's & Dementia. 4: T787-T788. DOI: 10.1016/J.Jalz.2008.05.2457  0.485
2008 Jackson M, Hendrix S, Zavitz K, Green RC, Schneider LS, Swabb E. P4-376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer's type (Act-Earli-AD): Rationale and methodology Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2446  0.443
2008 Horton S, Hendrix S, Johnson T, Zavitz K, Green RC, Schneider LS, Swabb E. P4-372: Comparison of a slopes analysis using a mixed model to a traditional change from baseline analysis in an Alzheimer's disease clinical trial setting Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2442  0.449
2008 Miller EA, Schneider LS, Rosenheck RA. P3-429: Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2000  0.304
2008 Schneider LS, Qizilbash N, Sano M, Massoud F, Kaye J, Olin JT, Laake K, Øksengaard AR, Oken BS, Yaffe K, Hashimoto K, López-Arrieta J, Breitner JCS, Flicker L, Rockwood K, et al. Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease) Evidence Based Dementia Practice. 467-588. DOI: 10.1002/9780470752340.ch34  0.65
2008 Yaari R, Tariot PN, Schneider LS, Roose SP. Cognitive Enhancers and Treatments for Alzheimer's Disease Psychiatry: Third Edition. 2: 2294-2317. DOI: 10.1002/9780470515167.ch107  0.305
2007 Schneider LS. Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Wuthering forest plots: distinguishing the forest from the plots. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 3: 18-20. PMID 19595911 DOI: 10.1016/J.Jalz.2006.10.003  0.474
2007 Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. The American Journal of Psychiatry. 164: 5-56. PMID 18340692  0.311
2007 Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Archives of General Psychiatry. 64: 1259-68. PMID 17984395 DOI: 10.1001/Archpsyc.64.11.1259  0.455
2007 Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet. Neurology. 6: 782-92. PMID 17689146 DOI: 10.1016/S1474-4422(07)70195-3  0.366
2007 Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics. Current Alzheimer Research. 4: 325-35. PMID 17627490 DOI: 10.2174/156720507781077214  0.451
2007 Winstein CJ, Bentzen KR, Boyd L, Schneider LS. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Current Alzheimer Research. 4: 273-6. PMID 17627484 DOI: 10.2174/156720507781077296  0.451
2007 Nelson JC, Delucchi K, Schneider L. Suicidal thinking and behavior during treatment with sertraline in late-life depression. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 15: 573-80. PMID 17586782 DOI: 10.1097/Jgp.0B013E318050C9C2  0.348
2007 Schneider L. Leon Thal and the Alzheimers Disease Cooperative Study Current Alzheimer Research. 4: 229-230. DOI: 10.2174/156720507780362182  0.428
2007 Hermans D, McShane R, Schneider LS. P-082: The Cochrane Dementia Group's study-based register of prevention trials Alzheimer's & Dementia. 3: S125-S125. DOI: 10.1016/J.Jalz.2007.04.335  0.408
2007 Tariot PN, Thal L, Jakimovich L, Schneider L, Cummings J, Raman R, Edland S. P-205: Valproate therapy to attenuate the clinical progression of Alzheimer's disease: Design of the ADCS valproate neuroprotection trial Alzheimer's & Dementia. 3: S163-S164. DOI: 10.1016/J.Jalz.2007.04.110  0.443
2006 Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Disease and Associated Disorders. 20: S124-38. PMID 17135806 DOI: 10.1097/01.Wad.0000213878.47924.44  0.404
2006 Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.Wad.0000213870.40300.21  0.456
2006 Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG. Design of Depression in Alzheimer's Disease Study-2. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 920-30. PMID 17068314 DOI: 10.1097/01.Jgp.0000240977.71305.Ee  0.442
2006 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. The New England Journal of Medicine. 355: 1525-38. PMID 17035647 DOI: 10.1056/Nejmoa061240  0.412
2006 Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 767-76. PMID 16905684 DOI: 10.1097/01.Jgp.0000196628.12010.35  0.392
2006 López‐Arrieta J, Schneider L. Metrifonate for Alzheimer's disease Cochrane Database of Systematic Reviews. PMID 16625573 DOI: 10.1002/14651858.Cd003155.Pub3  0.437
2006 Mintzer J, Greenspan A, Caers I, Van Hove I, Kushner S, Weiner M, Gharabawi G, Schneider LS. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 280-91. PMID 16505133 DOI: 10.1097/01.JGP.0000194643.63245.8c  0.365
2006 Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 14: 191-210. PMID 16505124 DOI: 10.1097/01.Jgp.0000200589.01396.6D  0.456
2006 Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews. PMID 16437436 DOI: 10.1002/14651858.Cd001747.Pub3  0.474
2006 Schneider LS. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London? International Journal of Geriatric Psychiatry. 21: 9-13. PMID 16353164 DOI: 10.1002/Gps.1492  0.459
2006 Schneider LS, Giacobini E. Metrifonate: A Cholinesterase Inhibitor for Alzheimer's Disease Therapy Cns Drug Reviews. 5: 13-26. DOI: 10.1111/J.1527-3458.1999.Tb00083.X  0.387
2006 Kennedy RE, Cutter GR, Fowler ME, Schneider LS. P4-015: RACIAL AND ETHNIC DIFFERENCES IN CONCOMITANT USE OF CHOLINESTERASE INHIBITORS AND MEMANTINE IN ALZHEIMER'S CLINICAL TRIALS Alzheimer's & Dementia. 14: P1437-P1437. DOI: 10.1016/J.Jalz.2018.06.2417  0.416
2006 Jacobs DM, Thomas RG, Salmon DP, Huisa BN, Feldman HH, Schneider LS. P3-032: SCREENING-TO-BASELINE COGNITIVE VARIABILITY DOES NOT PREDICT RATE OF DECLINE IN A CLINICAL TRIAL OF MILD-TO-MODERATE AD Alzheimer's & Dementia. 14: P1076-P1077. DOI: 10.1016/J.Jalz.2018.06.1387  0.398
2006 Hernandez GD, Lopez C, Desai MK, Kono N, Irwin RW, Rodgers KE, Mack WJ, Rogawski MA, Schneider LS, Brinton RD. P1-053: PHARMACOKINETICS AND SAFETY PROFILE OF INTRAVENOUS ADMINISTRATION OF ALLOPREGNANOLONE IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P288-P288. DOI: 10.1016/J.Jalz.2018.06.055  0.393
2006 Wang Y, Solinsky CM, Hernandez GD, Schneider LS, Brinton RD. P1-018: MITOCHONDRIAL HAPLOGROUP IN COMBINATION WITH APOE GENOTYPE AS POTENTIAL PREDICTIVE BIOMARKER TO IDENTIFY RESPONDERS TO REGENERATIVE THERAPEUTIC ALLOPREGNANOLONE FOR ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P271-P272. DOI: 10.1016/J.Jalz.2018.06.019  0.359
2006 Schneider L. S5-04-06: Discussion of the AD 2000 study Alzheimer's & Dementia. 2: S94-S94. DOI: 10.1016/J.Jalz.2006.05.374  0.374
2005 Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Current Alzheimer Research. 2: 541-51. PMID 16375657 DOI: 10.2174/156720505774932287  0.419
2005 Schneider LS. Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment. Alzheimer Disease and Associated Disorders. 19: 279-83. PMID 16327360 DOI: 10.1097/01.Wad.0000190808.97878.B8  0.41
2005 Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial American Journal of Geriatric Psychiatry. 13: 942-949. PMID 16286437 DOI: 10.1097/00019442-200511000-00004  0.447
2005 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Jama. 294: 1934-43. PMID 16234500 DOI: 10.1001/Jama.294.15.1934  0.414
2005 Nelson JC, Clary CM, Leon AC, Schneider LS. Symptoms of late-life depression: frequency and change during treatment. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 13: 520-6. PMID 15956272 DOI: 10.1097/00019442-200506000-00011  0.318
2005 Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. International Journal of Geriatric Psychiatry. 20: 119-27. PMID 15660424 DOI: 10.1002/Gps.1261  0.439
2004 Loy C, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Database of Systematic Reviews. CD001747. PMID 15495017 DOI: 10.1002/14651858.Cd001747.Pub2  0.414
2004 Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet. 363: 2100-1. PMID 15220027 DOI: 10.1016/S0140-6736(04)16533-1  0.446
2004 Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease Journal of the American Geriatrics Society. 52: 1070-1076. PMID 15209643 DOI: 10.1111/j.1532-5415.2004.52303.x  0.392
2004 Schneider LS. Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents. Evidence-Based Mental Health. 7: 47. PMID 15107343 DOI: 10.1136/Ebmh.7.2.47  0.31
2004 Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. The American Journal of Psychiatry. 161: 532-8. PMID 14992980 DOI: 10.1176/Appi.Ajp.161.3.532  0.412
2004 Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. Journal of Psychiatric Research. 38: 105-11. PMID 14690773 DOI: 10.1016/S0022-3956(03)00092-X  0.454
2004 Schneider L. P1-361 Alzheimer's disease cooperative study prevention instrument project: ADCS-clinician's global impression of change scales (ADCS-CGIC) Neurobiology of Aging. 25: S200-S201. DOI: 10.1016/S0197-4580(04)80673-0  0.385
2004 Ismail MS, Schneider LS, Tariot P, Dagerman KS, Davis S. P1-320 NIMH comparative effectiveness of antipsychotic medications in patients with Alzheimer's disease (CATIE-AD): clinical course Neurobiology of Aging. 25: S188. DOI: 10.1016/S0197-4580(04)80633-X  0.457
2004 Schneider L, Dagerman K. P1-309 Meta-analysis of atypical antipsychotics for aggression and psychosis in Alzheimer's disease: likelihood of helping versus harming Neurobiology of Aging. 25: S184. DOI: 10.1016/S0197-4580(04)80622-5  0.42
2004 Hake AM, Schneider LS, Tariot PN, Farlow MR. P1-063 The rate of decline in mild to moderate stage Alzheimer disease is associated with increased symptoms of depression Neurobiology of Aging. 25: S113. DOI: 10.1016/S0197-4580(04)80377-4  0.377
2003 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, et al. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Review of Neurotherapeutics. 3: 99-106. PMID 19810852 DOI: 10.1586/14737175.3.1.99  0.695
2003 Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. The Journal of Clinical Psychiatry. 64: 1065-74. PMID 14628982 DOI: 10.4088/Jcp.V64N0912  0.34
2003 Schneider LS. Cholinesterase inhibitors for vascular dementia? The Lancet. Neurology. 2: 658-9. PMID 14572732 DOI: 10.1016/S1474-4422(03)00581-7  0.305
2003 Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin. 29: 57-72. PMID 12908661 DOI: 10.1093/Oxfordjournals.Schbul.A006991  0.7
2003 Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 11: 414-25. PMID 12837670 DOI: 10.1097/00019442-200307000-00004  0.436
2003 Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. The American Journal of Psychiatry. 160: 1277-85. PMID 12832242 DOI: 10.1176/Appi.Ajp.160.7.1277  0.35
2003 Schneider LS. Cholinesterase inhibitors for Alzheimer disease. Jama. 289: 2359-60; author repl. PMID 12746354 DOI: 10.1001/Jama.289.18.2359-C  0.402
2003 Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Archives of Neurology. 60: 209-12. PMID 12580705 DOI: 10.1001/Archneur.60.2.209  0.322
2003 Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Current Drug Targets. 4: 97-112. PMID 12558063 DOI: 10.2174/1389450033346957  0.414
2003 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand OP, Jeste DV, Krishnan KRR, Lyketsos CG, Lyness JM, Rabins PV, et al. Diagnostic criteria for Depression of Alzheimer disease (DAD) Research and Practice in Alzheimer's Disease. 7: 174-179.  0.637
2003 Schneider LS. Potential noncholinnergic strategies for Alzheimer's disease Geriatrics. 58: 4-8.  0.313
2002 Finucane TE, Schneider LS. Cholinesterase inhibitors for Alzheimer's disease [3] (multiple letters) Lancet. 360: 1332-1333. PMID 12414234  0.301
2002 Olin JT, Dagerman KS, Fox LS, Bowers B, Schneider LS. Increasing ethnic minority participation in Alzheimer disease research. Alzheimer Disease and Associated Disorders. 16: S82-5. PMID 12351920 DOI: 10.1097/00002093-200200002-00009  0.65
2002 Tractenberg RE, Gamst A, Thomas RG, Patterson M, Schneider LS, Thal LJ. Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences. 14: 303-10. PMID 12154155 DOI: 10.1176/Jnp.14.3.303  0.391
2002 Schneider LS. Galantamine for vascular dementia: some answers, some questions. Lancet. 359: 1265-6. PMID 11965268 DOI: 10.1016/S0140-6736(02)08283-1  0.306
2002 Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 129-41. PMID 11925274 DOI: 10.1097/00019442-200203000-00004  0.682
2002 Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, et al. Provisional diagnostic criteria for depression of Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 10: 125-8. PMID 11925273 DOI: 10.1097/00019442-200203000-00003  0.682
2002 Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. The Cochrane Database of Systematic Reviews. CD000359. PMID 11405961 DOI: 10.1002/14651858.Cd000359  0.706
2002 Schneider LS. Cholinesterase inhibitors for Alzheimer's disease The Lancet. 360: 1332-1333. DOI: 10.1016/S0140-6736(02)11329-8  0.42
2001 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 400-5. PMID 11739066 DOI: 10.1097/00019442-200111000-00008  0.67
2001 Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 9: 346-60. PMID 11739062 DOI: 10.1097/00019442-200111000-00004  0.694
2001 Schneider LS. Assessing outcomes in Alzheimer disease. Alzheimer Disease and Associated Disorders. 15: S8-18. PMID 11669509 DOI: 10.1097/00002093-200108001-00003  0.452
2001 Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? International Journal of Geriatric Psychiatry. 16: 653-66. PMID 11466744 DOI: 10.1002/Gps.496  0.485
2001 Schneider LS. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clinics in Geriatric Medicine. 17: 337-58. PMID 11375139 DOI: 10.1016/S0749-0690(05)70072-0  0.429
2001 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease American Journal of Geriatric Psychiatry. 9: 400-405. DOI: 10.1097/00019442-200111000-00008  0.641
2001 Tariot PN, Schneider LS, Mintzer JE, Cutler AJ, Cunningham MR, Thomas JW, Sommerville KW. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial Current Therapeutic Research. 62: 51-67. DOI: 10.1016/S0011-393X(01)80042-4  0.378
2000 Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 55: 1271-8. PMID 11087767 DOI: 10.1212/Wnl.55.9.1271  0.441
2000 Tractenberg RE, Jin S, Patterson M, Schneider LS, Gamst A, Thomas RG, Thal LJ. Qualifying change: a method for defining clinically meaningful outcomes of change score computation. Journal of the American Geriatrics Society. 48: 1478-82. PMID 11083327 DOI: 10.1111/Jgs.2000.48.11.1478  0.406
2000 Schneider LS. Improving the conduct and reporting of clinical trials. Jama. 283: 2788; author reply 2. PMID 10838635 DOI: 10.1001/Jama.283.21.2787  0.341
2000 Schneider LS. Metrifonate for Alzheimer's disease patients. The Journal of Clinical Psychiatry. 61: 218-9. PMID 10817111 DOI: 10.4088/Jcp.V61N0312D  0.43
2000 Schneider LS. Do We Need a Meta-Analysis Update on Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia? International Psychogeriatrics. 12: 305-311. DOI: 10.1017/S1041610200007183  0.37
2000 Qizilbash N, Schneider LS. Can we trust meta-analysis in dementia? Neurobiology of Aging. 21: 241. DOI: 10.1016/S0197-4580(00)83421-1  0.347
2000 Qizilbash N, Schneider LS. Why does dementia need large pragmatic trials? Neurobiology of Aging. 21: 25. DOI: 10.1016/S0197-4580(00)82791-8  0.413
2000 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. Targeting specific behavioral symptoms in Alzheimer's disease using carbamazepine: Results of a pilot, placebo-controlled, randomized, 6-week trial Neurobiology of Aging. 21: 169. DOI: 10.1016/S0197-4580(00)82098-9  0.683
2000 Schneider LS, Tariot P, Lebowitz B. Health outcomes and effectiveness of atypical antipsychotics in outpatients with psychosis or agitation associated with AD Neurobiology of Aging. 21: 166. DOI: 10.1016/S0197-4580(00)82086-2  0.311
1999 Ippen CG, Olin JT, Schneider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients?: A longitudinal analysis. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 7: 321-30. PMID 10521165 DOI: 10.1097/00019442-199911000-00008  0.686
1999 Sands LP, Katz I, Schneider L. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors Alzheimer Disease and Associated Disorders. 13: 26-33. PMID 10192639 DOI: 10.1097/00002093-199903000-00004  0.388
1999 Ippen CG, Olin JT, Schneider LS. Can Caregivers Independently Rate Cognitive and Behavioral Symptoms in Alzheimerʼs Disease Patients? American Journal of Geriatric Psychiatry. 7: 321-330. DOI: 10.1097/00019442-199923740-00008  0.642
1999 Schneider L, Arvanitis L, Sweitzer D, Yeung P. QUETIAPINE MAY REDUCE HOSTILITY IN PATIENTS WITH PSYCHOSES RELATED TO ALZHEIMER's DISEASE The American Journal of Geriatric Psychiatry. 7: 58. DOI: 10.1097/00019442-199911001-00165  0.427
1999 Ippen CG, Olin JT, Schneider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients? A longitudinal analysis American Journal of Geriatric Psychiatry. 7: 321-330. DOI: 10.1097/00019442-199911000-00008  0.659
1998 Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials Jama. 280: 1777-1782. PMID 9842955 DOI: 10.1001/Jama.280.20.1777  0.435
1998 Fox LS, Olin JT, Erblich J, Ippen CG, Schneider LS. Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT). International Journal of Geriatric Psychiatry. 13: 544-9. PMID 9733335 DOI: 10.1002/(Sici)1099-1166(199808)13:8<544::Aid-Gps821>3.0.Co;2-N  0.655
1998 Schneider LS. Advances in the treatment of Alzheimer's disease. Aging (Milan, Italy). 10: 156-7. PMID 9666210  0.315
1998 Schneider LS. Cholinergic deficiency in Alzheimer's disease. Pathogenic model. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 6: S49-55. PMID 9581221 DOI: 10.1097/00019442-199821001-00007  0.38
1998 Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 50: 669-77. PMID 9521254 DOI: 10.1212/Wnl.50.3.669  0.455
1998 Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Archives of Neurology. 55: 41-51. PMID 9443710 DOI: 10.1001/Archneur.55.1.41  0.31
1998 Smith F, Gracon S, Knopman D, Schneider L. Tacrine Treatment and Nursing Home Placement: Application of the Cox Proportional Hazards Model With Time-Dependent Covariates Drug Information Journal. 32: 729-735. DOI: 10.1177/009286159803200312  0.325
1997 Buckwalter JG, Schneider LS, Wilshire TW, Dunn ME, Henderson VW. Body weight, estrogen and cognitive functioning in Alzheimer's disease: an analysis of the Tacrine Study Group data. Archives of Gerontology and Geriatrics. 24: 261-7. PMID 15374113 DOI: 10.1016/S0167-4943(96)00763-7  0.345
1997 Porsteinsson AP, Tariot PN, Schneider LS. Mood Disturbances in Alzheimer's Disease. Seminars in Clinical Neuropsychiatry. 2: 265-275. PMID 10320470 DOI: 10.1053/SCNP00200265  0.302
1997 Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. The American Journal of Medicine. 103: 46S-50S. PMID 9344406 DOI: 10.1016/S0002-9343(97)00257-X  0.428
1997 Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. Jama. 278: 1363-71. PMID 9343469 DOI: 10.1001/Jama.1997.03550160083043  0.399
1997 Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. Annals of the New York Academy of Sciences. 826: 317-22. PMID 9329702 DOI: 10.1111/J.1749-6632.1997.Tb48482.X  0.411
1997 Schneider LS, Finch CE. Can estrogens prevent neurodegeneration? Drugs & Aging. 11: 87-95. PMID 9259172 DOI: 10.2165/00002512-199711020-00001  0.452
1997 Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of the American Geriatrics Society. 45: 923-8. PMID 9256842 DOI: 10.1111/J.1532-5415.1997.Tb02960.X  0.702
1997 Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S51-6. PMID 9236953  0.373
1997 Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S22-32. PMID 9236949 DOI: 10.1097/00002093-199700112-00004  0.669
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 11: S1-12. PMID 9236947  0.413
1997 Tariot PN, Schneider L, Porsteinsson AP. Treating Alzheimer's disease. Pharmacologic options now and in the near future. Postgraduate Medicine. 101: 73-6, 81, 84 passim. PMID 9194867 DOI: 10.3810/Pgm.1997.06.224  0.424
1997 Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England Journal of Medicine. 336: 1216-22. PMID 9110909 DOI: 10.1056/Nejm199704243361704  0.425
1997 Class CA, Schneider L, Farlow MR. Optimal management of behavioural disorders associated with dementia. Drugs & Aging. 10: 95-106. PMID 9061267 DOI: 10.2165/00002512-199710020-00003  0.321
1997 Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen Replacement and Response to Fluoxetine in a Multicenter Geriatric Depression Trial American Journal of Geriatric Psychiatry. 5: 97-106. DOI: 10.1097/00019442-199700520-00002  0.365
1997 Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ. The Severe Impairment Battery Alzheimer Disease & Associated Disorders. 11: 51-56. DOI: 10.1097/00002093-199700112-00008  0.419
1997 Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders. 11: 1-12. DOI: 10.1097/00002093-199700112-00002  0.398
1997 Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Alzheimer Disease & Associated Disorders. 11: 425-429. DOI: 10.1007/978-1-4612-4116-4_64  0.671
1996 Schneider LS. Meta-analysis of controlled pharmacologic trials. International Psychogeriatrics / Ipa. 8: 375-9; discussion 38. PMID 9154592 DOI: 10.1017/S1041610297003669  0.312
1996 Schneider LS, Olin JT. Clinical global impressions in Alzheimer's clinical trials. International Psychogeriatrics / Ipa. 8: 277-88; discussion 2. PMID 8994897 DOI: 10.1017/S1041610296002645  0.696
1996 Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, Reisberg B, Schmitt FA. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. Journal of Geriatric Psychiatry and Neurology. 9: 176-80. PMID 8970010 DOI: 10.1177/089198879600900404  0.709
1996 Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S. Long-term tacrine (Cognex) treatment Effects on nursing home placement and mortality Neurology. 47: 166-177. PMID 8710072 DOI: 10.1212/Wnl.47.1.166  0.34
1996 Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46: 1580-4. PMID 8649552 DOI: 10.1212/Wnl.46.6.1580  0.429
1996 Small GW, Schneider LS, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB. Site Variability In A Multisite Geriatric Depression Trial International Journal of Geriatric Psychiatry. 11: 1089-1095. DOI: 10.1002/(Sici)1099-1166(199612)11:12<1089::Aid-Gps463>3.0.Co;2-F  0.342
1995 Schneider LS, Olin JT. Efficacy of acute treatment for geriatric depression. International Psychogeriatrics / Ipa. 7: 7-25. PMID 8580394 DOI: 10.1017/S1041610295002328  0.64
1995 Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. Journal of Geriatric Psychiatry and Neurology. 8: S28-39. PMID 8561842 DOI: 10.1177/089198879500800105  0.381
1995 Holt LE, Raine A, Pa G, Schneider LS, Henderson VW, Pollock VE. P300 topography in Alzheimer's disease. Psychophysiology. 32: 257-65. PMID 7784534 DOI: 10.1111/J.1469-8986.1995.Tb02954.X  0.353
1995 Schneider LS, Farlow MR. Predicting Response to Cholinesterase Inhibitors in Alzheimerʼs Disease Cns Drugs. 4: 114-124. DOI: 10.2165/00023210-199504020-00004  0.369
1995 Olin JT, Schneider LS. Assessing response to tacrine using the factor analytic structure of the Alzheimer's disease assessment scale (Adas)—cognitive subscale International Journal of Geriatric Psychiatry. 10: 753-756. DOI: 10.1002/Gps.930100905  0.684
1995 Finkel SI, Lyons JS, Anderson RL, Sherrell K, Davis J, Cohen-Mansfield J, Schwartz A, Gandy J, Schneider L. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients' International Journal of Geriatric Psychiatry. 10: 129-136. DOI: 10.1002/Gps.930100208  0.354
1994 Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Archives of Neurology. 51: 787-98. PMID 8042927 DOI: 10.1001/Archneur.1994.00540200063018  0.682
1994 Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications. The Medical Clinics of North America. 78: 911-34. PMID 8022237 DOI: 10.1016/S0025-7125(16)30142-0  0.49
1994 Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Archives of Neurology. 51: 676-81. PMID 8018040 DOI: 10.1001/Archneur.1994.00540190056015  0.434
1994 Schneider LS, Tariot PN, Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clinical Pharmacology and Therapeutics. 56: 750-6. PMID 7995017 DOI: 10.1038/Clpt.1994.205  0.343
1993 Schneider LS, Olin JT, Pawluczyk S. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. The American Journal of Psychiatry. 150: 321-3. PMID 8422085  0.655
1993 Schneider LS, Martinez RA, Lebowitz BD. Clinical psychopharmacology research in geriatrics: An agenda for research International Journal of Geriatric Psychiatry. 8: 89-93. DOI: 10.1002/Gps.930080113  0.389
1992 Schneider LS. Tracking dementia by the IMC and the MMSE. Journal of the American Geriatrics Society. 40: 537-8. PMID 1634715 DOI: 10.1111/J.1532-5415.1992.Tb02030.X  0.32
1992 Schneider LS, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in Alzheimer's disease. Biological Psychiatry. 31: 205-8. PMID 1531304 DOI: 10.1016/0006-3223(92)90206-F  0.374
1992 Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. The New England Journal of Medicine. 327: 1253-9. PMID 1406817 DOI: 10.1056/Nejm199210293271801  0.383
1992 Schneider LS, Sobin PB. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacology Bulletin. 28: 71-9. PMID 1351687  0.309
1992 Olin JT, Schneider LS, Eaton EM, Zemansky MF, Pollock VE. The Geriatric Depression Scale and the Beck Depression Inventory as Screening Instruments in an Older Adult Outpatient Population Psychological Assessment. 4: 190-192. DOI: 10.1037/1040-3590.4.2.190  0.603
1991 Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: A selective review International Journal of Geriatric Psychiatry. 6: 691-708. DOI: 10.1002/Gps.930061003  0.369
1990 Pollock VE, Schneider LS. The electroretinogram in Alzheimer's disease. Annals of Neurology. 28: 724-5. PMID 2260864 DOI: 10.1002/Ana.410280524  0.434
1990 Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society. 38: 553-63. PMID 1970586 DOI: 10.1111/J.1532-5415.1990.Tb02407.X  0.422
1990 Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. The Journal of Clinical Psychiatry. 51: 115-8. PMID 1968457  0.319
1990 Schneider LS. Tacrine and lecithin in Alzheimer's disease Bmj. 300: 940-940. DOI: 10.1136/bmj.300.6729.940-b  0.325
1989 Pollock VE, Schneider LS, Chui HC, Henderson V, Zemansky M, Sloane RB. Visual evoked potentials in dementia: a meta-analysis and empirical study of Alzheimer's disease patients. Biological Psychiatry. 25: 1003-13. PMID 2720014 DOI: 10.1016/0006-3223(89)90288-6  0.352
1989 Henderson VW, Roberts E, Wimer C, Bardolph EL, Chui HC, Damasio AR, Eslinger PJ, Folstein MF, Schneider LS, Teng EL. Multicenter trial of naloxone in Alzheimer's disease. Annals of Neurology. 25: 404-6. PMID 2653175 DOI: 10.1002/Ana.410250413  0.457
1988 Schneider LS, Severson JA, Chui HC, Pollock VE, Sloane RB, Fredrickson ER. Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions. Psychiatry Research. 25: 311-22. PMID 2847206 DOI: 10.1016/0165-1781(88)90101-1  0.365
1986 Schneider LS, Sloane RB, Staples FR, Bender M. Pretreatment orthostatic hypotension as a predictor of response to nortriptyline in geriatric depression. Journal of Clinical Psychopharmacology. 6: 172-6. PMID 3711368 DOI: 10.1097/00004714-198606000-00010  0.306
Show low-probability matches.